Pay in 4 interest-free payments of $7.22 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Once a month injections may be required
Lower levels of maternal serum PP13 in the first trimester are associated with the development of PE and intrauterine growth restriction (193, 270, 271)
Retatrutide is an investigational peptide drug developed by Eli Lilly that acts as a triple agonist, simultaneously targeting three hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors
2017;6(7):e004947
M., Meyer, K., & Murphy, M
US$ 24.51
US$ 25.65
US$ 26.47
US$ 24.35
US$ 29.63
US$ 29.37
US$ 25.32
US$ 25.07
US$ 21.61
